Singla, HeenaMunshi, AnjanaBanipal, Raja Paramjit SinghKumar, Vinod2018-07-142024-08-142018-07-142024-08-142018Singla, H., Munshi, A., Banipal, R. P. S., & Kumar, V. (2018). Recent updates on the therapeutic potential of HER2 tyrosine kinase inhibitors for the treatment of breast cancer. Current Cancer Drug Targets, 18(4), 306-327. doi: 10.2174/15680096176661706231222131568009610.2174/1568009617666170623122213http://10.2.3.109/handle/32116/1446HER2 positive breast cancer is characterized by the low survival rate in the metastatic patients. Development of resistance and disease-relapse are the major problems associated with the currently available therapies for HER2 positive breast cancer. There are two major targeted therapies for HER2 positive breast cancer viz. monoclonal antibodies and tyrosine-kinase inhibitors, and both of these therapies have their advantages and limitations. To address the limitations associated with the existing therapies, use of antibodies and TKIs as combination therapy proved to be more effective. Various chemical modifications can be performed on tyrosine-kinase inhibitors to develop novel ligands with increased selectivity for HER2 kinase. A number of tyrosine-kinase inhibitors are in various phases of clinical trials for the treatment of HER2 positive breast cancer. In the current review article, recent developments on various HER2 tyrosine-kinase inhibitors have been reported. Various structurally different scaffolds bind to the HER2 receptor and exhibit potent anti-cancer activities. The structural and pharmacophoric requirements of the scaffolds are discussed in detail so as to discover effective drug candidates for the treatment of HER2 positive breast cancer. ? 2018 Bentham Science Publishers.en-US4 [1 (3 fluorobenzyl) 5 indazolylamino] 5 methylpyrrolo[2,1 f][1,2,4]triazine 6 carbamic acid 3 morpholinomethyl ester6 [4 (4 ethyl 1 piperazinylmethyl)phenyl] 4 (alpha methylbenzylamino) 7h pyrrolo[2,3 d]pyrimidineafatinibbms 690514canertinibcp 724714cudc 101dacomitinibepertinibepidermal growth factor receptorepidermal growth factor receptor 2epidermal growth factor receptor kinase inhibitorkbp 5209lapatinibmubritinibn [4 [3 chloro 4 (3 fluorobenzyloxy)anilino] 6 qReviewhttp://www.eurekaselect.com/153604/article